CHICAGO TRUST Co NA Has $1.13 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

CHICAGO TRUST Co NA cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,733 shares of the company’s stock after selling 1,257 shares during the period. CHICAGO TRUST Co NA’s holdings in IDEXX Laboratories were worth $1,130,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Private Advisor Group LLC grew its holdings in shares of IDEXX Laboratories by 8.7% during the 2nd quarter. Private Advisor Group LLC now owns 2,287 shares of the company’s stock valued at $1,114,000 after purchasing an additional 183 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $89,000. DekaBank Deutsche Girozentrale boosted its position in IDEXX Laboratories by 3.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 54,220 shares of the company’s stock worth $26,721,000 after buying an additional 1,963 shares during the period. Zions Bancorporation N.A. increased its position in IDEXX Laboratories by 6.7% in the 2nd quarter. Zions Bancorporation N.A. now owns 496 shares of the company’s stock valued at $242,000 after acquiring an additional 31 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of IDEXX Laboratories by 1.0% during the second quarter. Parallel Advisors LLC now owns 2,595 shares of the company’s stock valued at $1,264,000 after acquiring an additional 26 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Activity at IDEXX Laboratories

In other news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.11% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Down 0.8 %

Shares of NASDAQ:IDXX traded down $3.22 during mid-day trading on Monday, hitting $414.83. 229,046 shares of the company traded hands, compared to its average volume of 502,553. The stock has a 50-day moving average price of $423.76 and a two-hundred day moving average price of $459.98. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The stock has a market cap of $33.97 billion, a P/E ratio of 40.00, a P/E/G ratio of 3.94 and a beta of 1.36. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.53 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Piper Sandler reiterated a “neutral” rating and set a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Barclays lowered their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Stifel Nicolaus dropped their price target on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $539.63.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.